AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05530902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Primary Rehabilitation Care
Description: As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
Study NCT05758298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-medicated gum
Description: Non-medicated, regular chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
Study NCT05758298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NICOTINE 2MG GUM
Description: Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
Study NCT05758298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NICOTINE 4MG GUM
Description: Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
Study NCT05929664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV
Study NCT05929664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05929664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT02526303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin Calcium and Warfarin
Description: Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
Study NCT06267690 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.
Study NCT05929664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05929664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05221255 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: spinal magnetic stimulation
Description: * Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~* Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~* Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds.
Study NCT05221255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal magnetic stimulation
Description: * Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~* Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~* Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds.
Study NCT04566757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Plasma
Description: Intravenous Infusion of Umbilical Cord Blood Plasma
Study NCT04970849 — intervention group
Intervention type: OTHER
Intervention: observation
Description: IBD doctors who perform the endoscopy perform the questionnaire
Study NCT05168176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotilavir sodium tablet
Description: The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
Study NCT05168176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dotilavir sodium tablet(Tivicay@)
Description: The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
Study NCT06343025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises Group
Description: Individuals will perform clinical pilates exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of basic pilates exercises, 10 minutes of warm-up and 5 minutes of cool-down exercises.
Study NCT06343025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercises Group
Description: Individuals will perform Tai Chi exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of Tai Chi movements, 10 minutes of warm-up and 5 minutes of cool-down exercises.
Study NCT05260606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 FDG PET/CT
Description: 1. 1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2. 2nd scan: interim~   * Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~  * Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3. 3rd scan: optional (3rd scan can be performed when disease progression is suspected)~4. Imaging~   * Fasting: at least 6 hours~  * Blood glucose level: \< 200 mg/dL~  * F-18 FDG 0.14 mCi/kg (IV)~  * Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~  * PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~  * First and second scans have to be performed with same scan.
Study NCT05184127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIR 19 ®
Description: Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
Study NCT05184127 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard COVID-19 therapy
Description: Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
Study NCT05184127 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard COVID-19 therapy
Description: Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
Study NCT05190536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ho:YAG lasers
Description: Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um Ho:YAG laser fiber was used for lithotripsy.Kidney stones were fragmented by Ho:YAG lasers, and sucked out by the suction sheath.
Study NCT05364060 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Different questionnaires detailed in the objectives part
Study NCT05476419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct intra-oral scanning technique for the post space.
Description: scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
Study NCT05476419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct intra-oral scanning technique for the post space.
Description: scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
Study NCT05190536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TFL
Description: Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um TFL fiber was used for lithotripsy.Kidney stones were fragmented by TFL, and sucked out by the suction sheath.
Study NCT05929664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05839639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NrtIs
Description: Subjects will receive NrtIs therapy for 24 weeks.
Study NCT05839639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-003
Description: Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.
Study NCT06341595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg iv q3w d1, 4-6 cycles
Study NCT06341595 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Extraperitoneal radiation therapy
Description: Radiotherapy using extraperitoneal radiation therapy, once a day, 5 times a week, 1.8-2 Gy/f, a total of 45-50.4 Gy (lymph node lesion radiation dose of 60-66 Gy)
Study NCT06341595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin: 130mg/m\^2, D1, Q3W, 4-6 cycles
Study NCT05839639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-003+NrtIs
Description: Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.
Study NCT06341595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1: 40mg/m\^2, bid, d1-14, 4-6 cycles
Study NCT06138808 — intervention group
Intervention type: OTHER
Intervention: Stereoelectroencephalography (SEEG)
Description: Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.
Study NCT04601974 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: lentiviral gene therapy
Description: lentiviral gene therapy to treat drug resistant epilepsy
Study NCT06406244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS group
Description: Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30 min before anesthesia until be discharged from the post-anaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
Study NCT06406244 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham group
Description: Patients in the sham group will receive electrode attachment but without stimulation.
Study NCT05393999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986414
Description: Broadly neutralising antibodies BMS-986414
Study NCT05393999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986413
Description: Broadly neutralising antibodies BMS-986413
Study NCT05163327 — intervention group
Intervention type: PROCEDURE
Intervention: Oxygen-enhanced Cardiac MRI
Description: The MRI scan will include assessment of cardiac function. Myocardial magnetic properties (T1, T2, T2\*) will be measured while patients are breathing room air, oxygen and during an infusion of adenosine. The scan will last for approximately 60 minutes. Prior to the scan patients will have an intravenous cannula (venflon) placed in an arm vein.
Study NCT06397859 — intervention group
Intervention type: DRUG
Intervention: Bulevirtide
Description: dose of 2 mg/day subcutaneously
Study NCT04926844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).
Study NCT04926844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
Study NCT04926844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
Study NCT04926844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
Study NCT04901806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200
Description: PBI-200 will be administered orally over continuous 28-day cycles
Study NCT05895123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Description: patients will receive one tablet rosuvastatin 20 mg every night
Study NCT05895123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: patients will receive one tablet Atorvastatin 40 mg every night
Study NCT04810403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOMEBODY Eating Disorder Prevention Program
Description: Participants will receive daily activities to complete on their most frequently used social media platform for 14 consecutive days. Daily activities have been adapted from the Body Project - an intervention that has been demonstrated to reduce internalization of the thin ideal and reduce risk for eating disorders. Examples of activities to be piloted include unfollowing social media accounts the participant perceives as reinforcing the thin-ideal and posting a selfie without makeup or editing. Based on feedback from participants, the intervention may be altered to improve acceptability, feasibility, and preliminary evidence of potential efficacy.
Study NCT06093945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554 tablet dosing
Description: SHR2554 350mg taken on Day 1 and Day 10
Study NCT06093945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole tablet dosing
Description: Omeprazole taken from Days 5 to Day 10
Study NCT05103475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rage Against the Pain (RAP)
Description: The sets of body positions used in the RAP program will mirror those used in the Hatha Yoga classes, but the RAP program will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the body positions (rather, positions will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the savasana exercise typically used in yoga practice).
Study NCT05103475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will comprise a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
Study NCT06146842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Each subject will receive allocated dose of bupivacaine
Study NCT05315635 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients treated for substance use disorders and patients treated for eating disorders will have to complete self-questionnaires and a clinical psychiatric (MINI) at the inclusion.~Patients suffering from substance use disorder will be assessed 3 weeks after inclusion.~Questionnaires are :~* Modified Yale Food Addiction (mYFAS 2.0) and Impulsive Behavior Scale (UPPS-P)~* Trait Meta-Mood Scale (TMMS), Hospital Anxiety and Depression Scale (HADs), Emotional Appetite Questionnaire (EMAQ), Perceived Stress Scale (PSS-10), Multidimensional Assessment of Interoceptive Awareness (MAIA) and Five Facet Mindfulness Questionnaire (FFMQ)~* Mini International Neuropsychiatric Interview (MINI), Eating Disorder Examination-Questionnaire (EDE-Q), Rosenberg's Self Esteem (RSE) and Ruminative Response Scale for Eating disorders (RRS-ED)~* Pittsburgh Sleep Quality Index (PSQI) and Montreal Cognitive Assessment (MoCA)
Study NCT05755022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary Segment Repositioning
Description: * Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using 3D photogrammetry technique.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed.
Study NCT05755022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Segment Repositioning
Description: * Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using the commercial scanners.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed.
Study NCT05211258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a novel portable upper gastrointestinal endoscopy system
Description: Patients arrived at the hospital in the morning after an overnight fast (>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
Study NCT05681338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the medium intensity coughing technique
Description: The medium intensity coughing technique: Immediately before the subcutaneous LMWH injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
Study NCT06192290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based transitional Cardiac Telerehabilitation
Description: This comprehensive series is divided into 16 parts, each addressing crucial aspects of open-heart surgery recovery. Part 1 introduces open-heart surgery, heart disease symptoms, and preoperative preparations for elderly patients. Part 2 delves into cardiac rehabilitation, defining objectives and detailing recovery stages. Part 3 covers care for surgical incisions and infection signs. Part 4 explores sleep and rest, while Part 5 guides patients on a healthy post-surgery diet. Part 6 focuses on nursing interventions for dyspnea, and Part 7 addresses post-surgery cough. Part 8 discusses nursing interventions for thrombosis prevention
Study NCT06104007 — intervention group
Intervention type: DEVICE
Intervention: Genoss® DCB
Description: This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
Study NCT05324592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW0813
Description: The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously.
Study NCT05324592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~One dose(2mg) of the drug will be injected intravitreously.
Study NCT05346276 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-hLAG-3 PET/CT
Description: Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
Study NCT04801485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-chiro inositol
Description: Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
Study NCT04801485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.